Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcus Biosciences, Inc. Common Stock (NY:RCUS)

22.74 +0.23 (+1.02%)
Delayed Quote Updated: 11:22 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arcus Biosciences, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
From Summit Therapeutics
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
From Arcus Biosciences
Via Business Wire
News headline image
Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Arcus Biosciences
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.